Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betuvax-CoV-2
- Development stage
- Phase 2
- Lead developer
- Artgen Biotech
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Betuvax-CoV-2 is a recombinant protein subunit vaccine for COVID-19 based on the S-protein RBD fused with the Fc-fragment of IgG. It uses spherical particles with a betulin-based adjuvant to enhance immunogenicity. The vaccine does not contain inactivated or weakened virus particles, vector viruses, genetic material (RNA or DNA), or inorganic adjuvants, making it potentially suitable for multiple revaccinations with minimal adverse reactions. Clinical trials have shown it to be safe and capable of inducing a strong humoral immune response.
- Brand names
- Betuvax-CoV-2Betuvax-CoV2Betuvax-CoV 2
- Other names
- БетуваксBetuvax
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on Betuvax-CoV-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Betuvax-CoV-2.